KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
117 hedge funds and large institutions have $605M invested in KalVista Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 44 increasing their positions, 16 reducing their positions, and 18 closing their positions.
200% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 18
175% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 16
100% more capital invested
Capital invested by funds: $303M → $605M (+$302M)
43% more funds holding
Funds holding: 82 → 117 (+35)
5.7% more ownership
Funds ownership: 91.33% → 97.03% (+5.7%)
57% less call options, than puts
Call options by funds: $3.59M | Put options by funds: $8.29M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$26.8M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$26.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$25.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$23.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$25.7M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$20.2M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.3M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$8.93M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Millennium Management
New York
| – | -$547K | -28,797 | Closed |
|
|
GCP
127
GSA Capital Partners
London,
United Kingdom
| – | -$430K | -22,664 | Closed |
|
|
EP
128
Eversept Partners
New York
| – | -$359K | -18,925 | Closed |
|
129
AllianceBernstein
Nashville,
Tennessee
| – | -$357K | -18,800 | Closed |
|
|
AG
130
Algert Global
San Francisco,
California
| – | -$230K | -12,119 | Closed |
|
|
NFG
131
Next Financial Group
Houston,
Texas
| – | -$86K | -4,525 | Closed |
|
|
CG
132
Cutler Group
San Francisco,
California
| – | -$18.4K | -700 | Closed |
|
|
DWA
133
Dorsey Wright & Associates
Pasadena,
California
| – | -$13K | -700 | Closed |
|
134
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$5K | -278 | Closed |
|
|
VFA
135
Valeo Financial Advisors
Carmel,
Indiana
| – | -$3K | -142 | Closed |
|
KALV Hedge Fund Activity: Q1 2021 in Review
117 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2021, worth a combined $605M — up 100% from $303M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new KALV positions and 18 closed out — a net gain of 36 holders — while 44 added to existing stakes and 16 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $26.8M. The largest seller was SV Health Investors, exiting entirely with an estimated $25.7M sold.
- 117 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2021, up from 82 in Q4 2020.
- Funds reported $605M of KalVista Pharmaceuticals stock for Q1 2021, up 100% quarter-over-quarter.
- 54 funds opened new KalVista Pharmaceuticals positions in Q1 2021 and 18 closed out, a net change of +36 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2021 was Deerfield Management, an estimated $26.8M added.
- The largest KalVista Pharmaceuticals seller in Q1 2021 was SV Health Investors, an estimated $25.7M sold.
Based on aggregated 13F filings for Q1 2021.